I. Jagroop

发表

The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease

G. Geroulakos, D. Mikhailidis, M. Matsagas, 2004, Platelets.

Homocysteine Activates Platelets In Vitro

D. Mikhailidis, G. Stansby, I. Jagroop, 2008, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT).

A. Seifalian, D. Mikhailidis, G. Hamilton, 2002, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan

D. Mikhailidis, I. Jagroop, 2000, Journal of Human Hypertension.

A New Rapid Method to Measure Human Platelet Cholesterol

D. Mikhailidis, D. Mikhailidis, I. Jagroop, 2011, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

The Relationship Between Circulating Fibrinogen and Lipoprotein (a) Levels in Patients With Primary Dyslipidemia

J. Papadakis, D. Mikhailidis, I. Gazi, 2007, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Doxazosin, an α1-adrenoceptor antagonist, inhibits serotonin-induced shape change in human platelets

D. Mikhailidis, I. Jagroop, 2001, Journal of Human Hypertension.

The Effect of Short-term Lipid Lowering with Atorvastatin on Carotid Artery Intima Media Thickness in Patients with Peripheral Vascular Disease: A Pilot Study

A. Seifalian, D. Mikhailidis, G. Hamilton, 2000, Current medical research and opinion.

Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia.

J. Papadakis, D. Mikhailidis, E. Ganotakis, 1999, American journal of hypertension.

Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease.

J. Papadakis, D. Mikhailidis, E. Ganotakis, 1999, International journal of cardiology.

Low-molecular-weight heparin during instability in coronary artery disease

A. Goodall, D. Mikhailidis, E. Ganotakis, 1996, The Lancet.

The effect of short-term lipid lowering with atorvastatin on carotid artery intima media thickness in patients with peripheral vascular disease: a pilot study.

A. Seifalian, D. Mikhailidis, G. Hamilton, 2000 .

Is clopidogrel markedly superior to aspirin in patients with peripheral vascular disease?

D. Mikhailidis, I. Jagroop, 1998, Platelets.

Plasma endothelin-1 concentrations in non-insulin-dependent diabetes mellitus and nondiabetic patients with chronic arterial obstructive disease of the lower limbs.

D. Mikhailidis, G. Stansby, I. Jagroop, 1999, International angiology : a journal of the International Union of Angiology.

'Effects of the angiotensin-converting enzyme inhibitor perindopril on endothelial and platelet function in essential hypertension'.

J. Papadakis, D. Mikhailidis, I. Jagroop, 1998, Platelets.

The paracrine endothelin system: pathophysiology and implications in clinical medicine.

R. Morgan, D. Mikhailidis, M. Dashwood, 1997, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

Mean platelet volume as an indicator of platelet activation: methodological issues

D. Mikhailidis, D. Mikhailidis, S. Tsiara, 2003, Platelets.

Lipoprotein (a) does not participate in the early acute phase response to training or extreme physical activity and is unlikely to enhance any associated immediate cardiovascular risk.

N. Milton, D. Mikhailidis, A. Winder, 2002, Journal of clinical pathology.

Does severity of ischaemic coronary disease correlate with erectile function?

D. Mikhailidis, I. Jagroop, C. Thompson, 1998, International Journal of Impotence Research.

The Effect of Tirofiban on Fibrinogen/Agonist-Induced Platelet Shape Change and Aggregation

D. Mikhailidis, I. Jagroop, 2008, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Beneficial effects of statins

D. Mikhailidis, E. Ganotakis, A. Winder, 1996, The Lancet.

Mean platelet volume in patients with type 2 diabetes mellitus

D. Mikhailidis, I. A. Jagroop, I. Jagroop, 2005, Platelets.

Effect of endothelin-1 on human platelet shape change: reversal of activation by naftidrofuryl.

D. Mikhailidis, I. Jagroop, 2000, Platelets.

Fibrinogen, lipoprotein (a) and lipids in patients with erectile dysfunction. A preliminary study.

R. Morgan, D. Mikhailidis, M. Miller, 2001, International angiology : a journal of the International Union of Angiology.

Naftidrofuryl inhibits the release of 5-hydroxytryptamine and platelet-derived growth factor from human platelets.

D. Mikhailidis, I. Jagroop, M. Barradas, 1994, Clinica chimica acta; international journal of clinical chemistry.

Statins and fibrinogen

D. Mikhailidis, A. Winder, I. Jagroop, 1998, The Lancet.

Aspirin increases platelet sensitivity to adenosine diphosphate in patients with coronary artery disease.

D. Mikhailidis, I. Jagroop, 1999, Platelets.

A low molecular weight heparin, nadroparin, (Fraxiparine), inhibits thrombin-induced platelet shape change and does not enhance spontaneous platelet aggregation (vol 41, pg 163, 1996)

D. Mikhailidis, I. Jagroop, M. Barradas, 1996 .

low molecular weight heparin, nadroparin (Fraxiparine), inhibits thrombin‐induced platelet shape change and does not enhance spontaneous platelet aggregation

D. Mikhailidis, D. Mikhailidis, I. Jagroop, 1996 .

Shape change in human platelets: measurement with a channelyzer and visualisation by electron microscopy.

D. Mikhailidis, D P Mikhailidis, I A Jagroop, 2000, Platelets.

The acute rise in plasma fibrinogen concentration with exercise is influenced by the G-453-A polymorphism of the beta-fibrinogen gene.

J. Deanfield, J. McEwan, J. Moult, 1996, Arteriosclerosis, thrombosis, and vascular biology.

A cross-sectional study of the effects of hormon replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women.

D. Mikhailidis, I. Jagroop, G. Prelevic, 2002, Fertility and sterility.

The Effects of Transdermal Estradiol Alone or with Cyclical Dydrogesterone on Markers of Cardiovascular Disease Risk in Postmenopausal Women with Type 2 Diabetes: A Pilot Study

D. Mikhailidis, N. Stojanović, D. Nair, 2003, Angiology.

Correlations between platelet aggregation, fibrinolysis, peripheral and central serotonergic measures in subhuman primates.

D. Mikhailidis, A. Winder, I. Jagroop, 1995, Atherosclerosis.

Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice.

K. Spyropoulos, D. Mikhailidis, E. Ganotakis, 1998, International angiology : a journal of the International Union of Angiology.

Endothelin-1 and human platelets.

S. Daskalopoulou, D. Mikhailidis, I. Jagroop, 2005, Current vascular pharmacology.

Heparin and platelet activation.

D. Mikhailidis, I. Jagroop, 2012, Thrombosis research.

Heparin Therapy Leads to Platelet Activation and Prolongation of Platelet Function Analyser-100 Closure Time

D. Mikhailidis, I. Jagroop, 2006, Journal of cardiovascular pharmacology and therapeutics.

Effect of Clopidogrel on Platelet Aggregation and Plasma Concentration of Fibrinogen in Subjects With Cerebral or Coronary Atherosclerotic Disease

D. Mikhailidis, I. Jagroop, Michelle Malley, 2002, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Regarding "Heparin modulates integrin function in human platelets".

D. Mikhailidis, I. Jagroop, 2002, Journal of vascular surgery.

Does severity of ischemic coronary disease correlate with erectile function?

R. Morgan, D. Mikhailidis, Z. Braf, 1997, International Journal of Impotence Research.

Platelets and vascular risk: an option for treatment.

D. Mikhailidis, I. Jagroop, A. Kakafika, 2007, Current pharmaceutical design.